Search

Search Constraints

You searched for: Subject immunotherapy -- lung neoplasms

Search Results

1. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. Issue 4 (7th April 2021)

2. EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma. Issue 2 (10th December 2020)

3. EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma. Issue 2 (10th December 2020)

4. Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. Issue 3 (18th March 2021)

5. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. Issue 2 (30th August 2020)

6. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. Issue 2 (30th August 2020)

7. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. Issue 2 (30th August 2020)

8. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. Issue 2 (30th August 2020)

9. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. Issue 2 (30th August 2020)

10. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. Issue 2 (30th August 2020)